Loading...

Insulet

DB:GOV
Snowflake Description

High growth potential with questionable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GOV
DB
$6B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
  • Insulet has significant price volatility in the past 3 months.
GOV Share Price and Events
7 Day Returns
1.3%
DB:GOV
1.4%
DE Medical Equipment
-0.3%
DE Market
1 Year Returns
28%
DB:GOV
20.2%
DE Medical Equipment
-7.5%
DE Market
GOV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Insulet (GOV) 1.3% 15.8% 36.6% 28% 222.8% 155.9%
DE Medical Equipment 1.4% 3.6% 9.8% 20.2% 79.9% 185.3%
DE Market -0.3% 1.8% 8.2% -7.5% 8.8% 9.4%
1 Year Return vs Industry and Market
  • GOV outperformed the Medical Equipment industry which returned 20.2% over the past year.
  • GOV outperformed the Market in Germany which returned -7.5% over the past year.
Price Volatility
GOV
Industry
5yr Volatility vs Market

GOV Value

 Is Insulet undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Insulet to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Insulet.

DB:GOV Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 19 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:GOV
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.93
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.933 (1 + (1- 21%) (9.8%))
1.003
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.003 * 5.96%)
6.21%

Discounted Cash Flow Calculation for DB:GOV using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Insulet is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:GOV DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.21%)
2019 -14.50 Analyst x2 -13.65
2020 109.35 Analyst x2 96.94
2021 158.90 Analyst x2 132.64
2022 208.70 Analyst x1 164.03
2023 271.00 Analyst x1 200.54
2024 320.49 Est @ 18.26% 223.31
2025 361.68 Est @ 12.85% 237.28
2026 394.47 Est @ 9.06% 243.67
2027 419.77 Est @ 6.41% 244.14
2028 438.90 Est @ 4.56% 240.35
Present value of next 10 years cash flows $1,769.24
DB:GOV DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $438.90 × (1 + 0.23%) ÷ (6.21% – 0.23%)
$7,357.71
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $7,357.71 ÷ (1 + 6.21%)10
$4,029.20
DB:GOV Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,769.24 + $4,029.20
$5,798.44
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $5,798.44 / 59.28
$97.82
DB:GOV Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:GOV represents 0.89207x of NasdaqGS:PODD
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.89207x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 97.82 x 0.89207
€87.26
Value per share (EUR) From above. €87.26
Current discount Discount to share price of €87.28
= -1 x (€87.28 - €87.26) / €87.26
-0%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Insulet is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Insulet's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Insulet's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:GOV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $0.06
NasdaqGS:PODD Share Price ** NasdaqGS (2019-03-22) in USD $97.84
Germany Medical Equipment Industry PE Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 31.73x
Germany Market PE Ratio Median Figure of 423 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Insulet.

DB:GOV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:PODD Share Price ÷ EPS (both in USD)

= 97.84 ÷ 0.06

1749.36x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Insulet is overvalued based on earnings compared to the DE Medical Equipment industry average.
  • Insulet is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Insulet's expected growth come at a high price?
Raw Data
DB:GOV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 1749.36x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 19 Analysts
42.7%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 2.81x
Germany Market PEG Ratio Median Figure of 275 Publicly-Listed Companies 1.41x

*Line of best fit is calculated by linear regression .

DB:GOV PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 1749.36x ÷ 42.7%

40.96x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Insulet is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Insulet's assets?
Raw Data
DB:GOV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $3.58
NasdaqGS:PODD Share Price * NasdaqGS (2019-03-22) in USD $97.84
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.31x
Germany Market PB Ratio Median Figure of 571 Publicly-Listed Companies 1.78x
DB:GOV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:PODD Share Price ÷ Book Value per Share (both in USD)

= 97.84 ÷ 3.58

27.3x

* Primary Listing of Insulet.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Insulet is overvalued based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess Insulet's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Insulet has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

GOV Future Performance

 How is Insulet expected to perform in the next 1 to 3 years based on estimates from 19 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
42.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Insulet expected to grow at an attractive rate?
  • Insulet's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Insulet's earnings growth is expected to exceed the Germany market average.
  • Insulet's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:GOV Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:GOV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 19 Analysts 42.7%
DB:GOV Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 19 Analysts 15.6%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 11.9%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 5.9%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.3%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:GOV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 19 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:GOV Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,324 200 2
2022-12-31 1,137 142 4
2021-12-31 978 199 85 9
2020-12-31 806 138 44 19
2019-12-31 680 88 12 19
DB:GOV Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 564 36 3
2018-09-30 529 27 -13
2018-06-30 500 35 -17
2018-03-31 486 59 -23
2017-12-31 464 41 -27
2017-09-30 437 39 -29
2017-06-30 410 19 -30
2017-03-31 387 5 -26
2016-12-31 367 16 -27
2016-09-30 347 -23 -34
2016-06-30 324 -17 -49
2016-03-31 297 -20 -62

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Insulet's earnings are expected to grow significantly at over 20% yearly.
  • Insulet's revenue is expected to grow by 15.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:GOV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 19 Analyst Estimates (S&P Global) See Below

All data from Insulet Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GOV Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.86 3.21 2.51 2.00
2022-12-31 2.23 2.61 1.83 3.00
2021-12-31 1.42 1.72 1.10 7.00
2020-12-31 0.71 0.97 0.51 15.00
2019-12-31 0.20 0.42 0.10 14.00
DB:GOV Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 0.06
2018-09-30 -0.23
2018-06-30 -0.30
2018-03-31 -0.40
2017-12-31 -0.46
2017-09-30 -0.50
2017-06-30 -0.52
2017-03-31 -0.46
2016-12-31 -0.48
2016-09-30 -0.59
2016-06-30 -0.86
2016-03-31 -1.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Insulet is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Insulet's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Insulet has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

GOV Past Performance

  How has Insulet performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Insulet's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insulet has delivered over 20% year on year earnings growth in the past 5 years.
  • Insulet has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Insulet has become profitable in the last year making it difficult to compare the DE Medical Equipment industry average.
Earnings and Revenue History
Insulet's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Insulet Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GOV Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 563.82 3.29 241.54 88.61
2018-09-30 529.44 -13.46 250.07 78.87
2018-06-30 500.14 -17.35 228.16 77.25
2018-03-31 485.63 -23.42 218.80 76.86
2017-12-31 463.77 -26.83 210.10 74.45
2017-09-30 436.82 -29.12 191.35 71.70
2017-06-30 409.92 -29.91 179.40 65.30
2017-03-31 387.49 -26.50 168.43 60.22
2016-12-31 366.99 -27.21 166.08 55.71
2016-09-30 347.22 -33.97 158.85 52.57
2016-06-30 323.74 -48.93 155.70 48.87
2016-03-31 296.96 -61.85 149.21 47.99
2015-12-31 263.89 -61.60 138.80 43.21
2015-09-30 252.65 -51.09 128.73 37.60
2015-06-30 256.25 -43.95 126.16 34.72
2015-03-31 267.71 -55.80 128.02 29.33
2014-12-31 231.32 -47.94 108.10 27.90
2014-09-30 284.69 -48.60 112.43 27.04
2014-06-30 270.81 -59.05 115.10 25.65
2014-03-31 258.89 -40.45 108.21 24.15
2013-12-31 247.08 -44.97 117.26 21.77
2013-09-30 236.38 -52.67 116.43 21.19
2013-06-30 230.03 -43.80 106.31 21.98
2013-03-31 220.97 -47.75 105.15 23.32
2012-12-31 211.37 -51.87 103.95 24.36
2012-09-30 200.73 -56.01 101.48 24.32
2012-06-30 190.58 -57.16 98.87 22.40
2012-03-31 171.75 -50.76 91.96 22.71

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Insulet has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Insulet used its assets less efficiently than the DE Medical Equipment industry average last year based on Return on Assets.
  • Insulet has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Insulet's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Insulet has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

GOV Health

 How is Insulet's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Insulet's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Insulet is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Insulet's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Insulet's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Insulet Company Filings, last reported 2 months ago.

DB:GOV Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 212.10 591.98 288.95
2018-09-30 197.93 584.49 289.84
2018-06-30 179.15 577.12 299.79
2018-03-31 170.57 573.33 352.00
2017-12-31 158.52 566.17 440.06
2017-09-30 74.25 344.95 275.76
2017-06-30 64.73 340.84 258.61
2017-03-31 63.59 336.76 254.03
2016-12-31 63.15 332.77 298.57
2016-09-30 65.10 330.02 282.70
2016-06-30 27.44 178.01 111.27
2016-03-31 26.40 178.13 111.64
2015-12-31 34.05 177.49 122.67
2015-09-30 55.13 180.95 145.47
2015-06-30 70.26 180.77 145.14
2015-03-31 80.74 180.56 145.61
2014-12-31 83.83 169.66 151.19
2014-09-30 80.34 174.50 146.37
2014-06-30 77.88 201.47 175.55
2014-03-31 122.49 123.69 145.61
2013-12-31 124.60 121.68 149.73
2013-09-30 121.43 119.80 153.91
2013-06-30 138.34 112.95 150.94
2013-03-31 129.55 120.92 148.07
2012-12-31 44.18 118.16 57.29
2012-09-30 50.45 115.65 63.44
2012-06-30 59.09 113.23 70.14
2012-03-31 70.22 110.84 83.01
  • Insulet's level of debt (279.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (97.7% vs 279.1% today).
  • Debt is not well covered by operating cash flow (6.1%, less than 20% of total debt).
  • Interest payments on debt are not well covered by earnings (EBIT is 1.8x annual interest expense, ideally 3x coverage).
X
Financial health checks
We assess Insulet's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Insulet has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

GOV Dividends

 What is Insulet's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Insulet dividends. Estimated to be 0% next year.
If you bought €2,000 of Insulet shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Insulet's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Insulet's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:GOV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 19 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 330 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:GOV Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Insulet has not reported any payouts.
  • Unable to verify if Insulet's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Insulet's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Insulet has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Insulet's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Insulet's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Insulet afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Insulet has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

GOV Management

 What is the CEO of Insulet's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Shacey Petrovic
COMPENSATION $3,655,408
AGE 44
TENURE AS CEO 0.2 years
CEO Bio

Ms. Shacey Petrovic is the President of Insulet Corporation since October, 2016 and its Director since September 10, 2018. She served as Chief Operating Officer of Insulet Corporation since October, 2016 until January 1, 2019. Previously, she served as its Executive Vice President and President of Diabetes Products from February 2016 until October, 2016. Ms. Petrovic served as the Chief Commercial Officer at Insulet Corporation since February 10, 2015 until February 2016. She served as a Senior Advisor at Pritzker Group Private Capital and worked closely with the healthcare investment team. She served two years as the Chief Executive Officer and President of Clinical Innovations, LLC. Her track record of increasing sustainable profitability aligns perfectly with Clinical Innovation's growth strategy. She joined Clinical Innovations from Hologic, where she served as Vice President and General Manager of its gynecologic surgical division. As Hologic's Vice President of global surgical marketing, she led a direct-to-consumer advertising campaign and the integration of Interlace Medical. She has execution skills and a proven ability to grow product lines and lead top performing teams. Prior to her tenure with Hologic, she served in sales and marketing leadership roles in the United States and Europe for Cytyc Corporation. She served in a number of key roles during 13 years at Hologic, Inc. and Cytyc Corporation. Ms. Petrovic served as an award-winning Pharmaceutical Sales Specialist at AstraZeneca. Ms. Petrovic's 15 years of progressive leadership in the healthcare industry includes global successes in new business development as well as product and market launches. She has a long track record of success within commercial operations, including new product introduction, market share growth and business development. She is a seasoned expert with nearly two decades of experience in the medical device industry. She earned her B.S. in Biology from the University of Wisconsin - Madison.

CEO Compensation
  • Shacey's compensation has increased in line with Insulet recently becoming profitable.
  • Shacey's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Insulet management team in years:

3
Average Tenure
58
Average Age
  • The tenure for the Insulet management team is about average.
Management Team

Shacey Petrovic

TITLE
President
COMPENSATION
$4M
AGE
44
TENURE
0.2 yrs

Charles Alpuche

TITLE
Executive VP & COO
COMPENSATION
$2M
AGE
58
TENURE
0.2 yrs

Pat Sullivan

TITLE
Consultant
COMPENSATION
$8M
AGE
66
TENURE
0.2 yrs

Mike Levitz

TITLE
COMPENSATION
$2M
AGE
44

Wayde McMillan

TITLE
Executive VP & CFO

Aiman Abdel-Malek

TITLE
Executive VP & Chief Technology Officer
AGE
60
TENURE
3 yrs

Deborah Gordon

TITLE
Vice President of Investor Relations & Corporate Communications
TENURE
4.2 yrs

Jack Kapples

TITLE
Senior VP
AGE
58

Phil Hildale

TITLE
Senior Vice President of Sales & Customer Care
TENURE
4.2 yrs

Christopher Gilbert

TITLE
Vice President of Marketing
TENURE
4.2 yrs
Board of Directors Tenure

Average tenure and age of the Insulet board of directors in years:

2.8
Average Tenure
58.5
Average Age
  • The average tenure for the Insulet board of directors is less than 3 years, this suggests a new board.
Board of Directors

Tim Scannell

TITLE
Chairman
COMPENSATION
$221K
AGE
53
TENURE
0.2 yrs

Shacey Petrovic

TITLE
President
COMPENSATION
$4M
AGE
44
TENURE
0.5 yrs

Robert Sherwin

TITLE
Chairman of Scientific Advisory Board

Sally Crawford

TITLE
Independent Director
COMPENSATION
$228K
AGE
64
TENURE
10.4 yrs

John Fallon

TITLE
Independent Director
COMPENSATION
$221K
AGE
70
TENURE
6.4 yrs

David Lemoine

TITLE
Independent Director
COMPENSATION
$237K
AGE
70
TENURE
3.1 yrs

Jessica Hopfield

TITLE
Lead Independent Director
COMPENSATION
$266K
AGE
53
TENURE
2.6 yrs

Howard Wolpert

TITLE
Member of Scientific Advisory Board

Margaret Lawlor

TITLE
Member of Educator Advisory Board

Camille Izlar

TITLE
Member of Educator Advisory Board
Who owns this company?
Recent Insider Trading
  • Insulet insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
06. Mar 19 Sell Aiman Abdel-Malek Individual 01. Mar 19 01. Mar 19 -1,608 €83.69 €-134,576
06. Mar 19 Sell David Lemoine Individual 01. Mar 19 01. Mar 19 -561 €82.87 €-46,490
X
Management checks
We assess Insulet's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Insulet has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

GOV News

Simply Wall St News

GOV Company Info

Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod. It sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, Israel, and internationally. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.

Details
Name: Insulet Corporation
GOV
Exchange: DB
Founded: 2000
$5,346,710,150
59,278,993
Website: http://www.insulet.com
Address: Insulet Corporation
100 Nagog Park,
Acton,
Massachusetts, 01720,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS PODD Common Stock Nasdaq Global Select US USD 15. May 2007
DB GOV Common Stock Deutsche Boerse AG DE EUR 15. May 2007
Number of employees
Current staff
Staff numbers
1,169
Insulet employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/22 21:04
End of day share price update: 2019/03/22 00:00
Last estimates confirmation: 2019/03/20
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.